Antibody drug conjugates: a novel approach and evaluation of efficacy and potency

The steady rise in antibody-drug conjugate (ADC) candidates over the past two decades reflects the growing recognition of their transformative potential in targeted cancer therapy. With more than 100 ADCs in clinical development and 15 approved treatments to date, the field continues to expand rapidly.

In this webinar, Revvity scientists will share insights into the latest advancements in ADC evaluation, highlighting innovative strategies and assays designed to assess efficacy and potency. Join us to explore how cutting-edge tools - from monitoring internalization using pHSense™ Eu reagents to high-throughput cell panel screening - can accelerate ADC and antibody discovery.

Speakers:

Eric Trinquet
Senior R&D Director Life Science Reagents, Revvity

Jack Taylor
Manager, Preclinical Services, Revvity

Hennique Erasmus, MSc.
Team leader, Preclinical Services, Revvity

For research use only. Not for use in diagnostic procedures.